Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Wednesday, setting a price target of $100, which is approximately 52.88% above the present share price of $65.41.
Schimmer expects Denali Therapeutics to post earnings per share (EPS) of -$0.58 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Denali Therapeutics, with an average price target of $86.6.
The analysts price targets range from a high of $100 to a low of $70.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $7.92 million and a net profit of -$71.22 million. The company's market cap is $7.93 billion.
According to TipRanks.com, Evercore ISI analyst Joshua Schimmer is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.2% and a 53.06% success rate.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.